Shots:  The EC has approved Remsima IV (100mg and 350mg vials), a liquid formulation, a biosimilar version of Remicade   The approval is supported by data showing the liquid and powder infliximab formulations are comparable in CMC characteristics and stability after reconstitution and dilution   The Remsima IV liquid formulation is EU-approved for all existing IV infliximab indications, including RA, adult and pediatric CD and UC,…